Evidence map›Paper›PMID 34532715›Full record

ArticleJournal of immunotherapy and precision oncology2020

Are Cancer Patients at Higher Risk of Death With COVID-19?

Jacob J Adashek, Joud Hajjar, Roy F Chemaly, Razelle Kurzrock

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotherapy and precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Depression and anxiety in cancer patients before and during the SARS-CoV-2 pandemic: association with treatment delays.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Article
  4. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.Journal of immunotherapy and precision oncology · 2021
    Article
  5. Article
  6. Review
  7. Developing Drugs for Sarcomas in a Brave New World.Journal of immunotherapy and precision oncology · 2020
    Article
  8. Repurposing Interleukin-6 Inhibitors to Combat COVID-19.Journal of immunotherapy and precision oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacob J AdashekDepartment of Internal Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Joud HajjarWilliam T Shearer, Department of Pediatrics, Center for Human Immunobiology, Section of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Houston, Texas, USA.
Roy F ChemalyDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Razelle KurzrockDepartment of Medicine, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancercoronavirusCOVID-19MERSSARS

Identifiers

PMID34532715
PMCPMC8442944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.